Evidence analysisOctober 22, 2026Health & Science

Human medicines European public assessment report (EPAR): GONAL-f, follitropin alfa, Date of authorisation: 20/10/1995, Revision: 28, Status: Authorised

FreedomWitness Evidence Engine: This is an AI-assisted original analysis built from the linked source and available public source context. It separates evidence from interpretation and may challenge conventional framing only where the evidence supports it. It is not a copied article.

What is established

GONAL-f, containing the active substance follitropin alfa, is a medicine authorised in the European Union since 1995. It is manufactured by Merck Serono Europe Ltd and is used primarily in fertility treatments.

Follitropin alfa is a recombinant form of the natural hormone follicle-stimulating hormone (FSH). In women, FSH stimulates the production and maturation of eggs in the ovaries. In men, it stimulates sperm production in the testicles.

GONAL-f is administered via daily subcutaneous injections, in the form of either a prefilled pen solution or reconstituted powder and solvent. Treatment is typically managed by doctors experienced in fertility treatment, with patients sometimes trained to self-administer.

The medicine is used for several groups:

  • Women who do not produce eggs or who do not respond to clomiphene citrate treatment
  • Women undergoing assisted reproductive techniques such as in-vitro fertilisation (IVF), where multiple eggs need to be stimulated
  • Women with severe deficiencies of luteinising hormone (LH) and FSH, often treated with GONAL-f plus LH-containing medicine
  • Men with hypogonadotrophic hypogonadism, often treated with GONAL-f in combination with human chorionic gonadotrophin (hCG) to stimulate sperm production

What the source claims

The European Medicines Agency (EMA) states that GONAL-f has demonstrated effectiveness comparable to human-derived FSH in several clinical studies. For example, among women who failed to produce eggs or respond to clomiphene citrate, 84% treated with GONAL-f produced eggs versus 91% with urinary FSH.

In assisted reproductive technology protocols, GONAL-f has efficacy similar to urine-derived FSH in stimulating follicles and eggs. In rare conditions of severe LH and FSH deficiency in women, GONAL-f combined with LH has successfully matured eggs.

In men with hormone deficiency, 63% started sperm production with GONAL-f plus hCG treatment.

The EMA emphasizes that the primary side effects include injection site reactions and ovarian cysts or headaches in women. There is a known risk of ovarian hyperstimulation syndrome (OHSS), a potentially serious condition requiring vigilance by physicians and patients.

Contraindications include hypersensitivity to components, certain hormone-related cancers, and situations unlikely to respond to stimulation, among others. The medication carries a marketing authorisation for unlimited use in the EU, attesting to ongoing regulatory approval.

What may be missing from the usual framing

The EMA summary does not provide comprehensive data on patient outcomes beyond stimulation results such as pregnancy rates, live birth rates, or long-term safety data. The presented studies are relatively small (e.g., 222 women with failed clomiphene response, 470 in ART settings, and limited patients in rare hormone deficiency groups).

While the clinical studies referenced compare GONAL-f mainly with urine-derived FSH, they do not present comparisons with other modern fertility drugs or protocols, limiting understanding of relative efficacy or safety in current practice.

Potential economic factors—such as treatment cost, access disparities, or pharmaceutical company incentives—are not addressed by the summary, which may impact patient experience and healthcare system decisions.

The information also does not discuss patient selection criteria in detail or the potential for off-label use, which are relevant in real-world treatment settings.

Competing evidence or uncertainty

The EMA document itself is based on clinical trial data submitted for regulatory approval. Evidence from independent or post-marketing real-world studies is not included here and may highlight different safety or efficacy concerns.

Because some patient groups treated with GONAL-f have rare conditions, trials included relatively few subjects, raising uncertainty about the generalisability of findings.

There is historically some debate in fertility medicine about the comparative advantages of recombinant versus urinary-derived FSH. While this source supports comparable efficacy, some academic literature or clinical guidelines may have divergent views based on different studies or practical experience.

Potential risks such as ovarian hyperstimulation syndrome, although acknowledged, require monitoring across broader patient populations to fully assess severity, frequency, and risk factors.

Why it matters

Infertility affects millions globally, and effective fertility treatments are crucial for many individuals and couples seeking to conceive. GONAL-f represents a widely used pharmaceutical agent that facilitates ovarian stimulation and sperm production in specific hormonal deficiencies.

Understanding the benefits, risks, and limitations of GONAL-f is vital for patients, clinicians, and healthcare systems in making informed treatment decisions. It impacts quality of care, patient safety, and health economics in reproductive medicine.

The use of recombinant DNA technology to produce a human-identical hormone also reflects broader trends in biopharmaceutical innovation that can offer advantages over traditional extraction methods but may pose cost or access considerations.

What to verify next

  • Updated clinical trial results or meta-analyses comparing GONAL-f with other fertility medications, particularly including pregnancy and live birth outcomes
  • Post-marketing surveillance data on safety, including the incidence and management of ovarian hyperstimulation syndrome in real-world settings
  • Independent studies on cost-effectiveness and patient access or satisfaction with GONAL-f treatment
  • Clinical guidelines and expert opinions addressing when GONAL-f is preferred or alternative treatments are indicated
  • Potential impacts of long-term hormone stimulation on patients’ health outcomes beyond the immediate fertility treatment window

Readers are encouraged to consult the original European Medicines Agency source for comprehensive details and consult healthcare professionals for personalized medical guidance.

Source & verification

Primary source: What's new · October 21, 2026

Read the original source

FreedomWitness links to the original source so readers can inspect the underlying material and judge the context for themselves.

Continue reading

Burkina Faso Targets Critics in Exile

Accountability in Burkina Faso: Evidence Dossier on Judicial Repression of Critics Abroad What is established Since a military coup in September 2022, the ruling…